HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis.
Chloé LoiseauDaniela BritesMiriam ReinhardKathrin ZürcherSonia BorrellMarie BallifLukas FennerHelen CoxLiliana K RutaihwaRobert J WilkinsonMarcel YotebiengE Jane CarterAlash'le AbimikuOlivier MarcyEduardo GotuzzoAnchalee AvihingsanonNicola ZetolaBasra DoullaErik C BöttgerMatthias EggerSebastien GagneuxPublished in: Antimicrobial agents and chemotherapy (2020)
We analyzed 312 drug-resistant genomes of Mycobacterium tuberculosis isolates collected from HIV-coinfected and HIV-negative TB patients from nine countries with a high tuberculosis burden. We found that rifampicin-resistant M. tuberculosis strains isolated from HIV-coinfected patients carried disproportionally more resistance-conferring mutations in rpoB that are associated with a low fitness in the absence of the drug, suggesting these low-fitness rpoB variants can thrive in the context of reduced host immunity.
Keyphrases
- mycobacterium tuberculosis
- antiretroviral therapy
- drug resistant
- hiv positive
- hiv aids
- hiv infected
- hiv testing
- human immunodeficiency virus
- pulmonary tuberculosis
- end stage renal disease
- hepatitis c virus
- body composition
- ejection fraction
- newly diagnosed
- physical activity
- chronic kidney disease
- men who have sex with men
- multidrug resistant
- prognostic factors
- escherichia coli
- emergency department
- gene expression
- patient reported outcomes
- copy number
- drug induced
- dna methylation
- adverse drug